Antihistaminics: block histamine effects, but choose the receptor, generation and clinical target correctly
“Antihistamine” usually means an H1-receptor antagonist/inverse agonist used for allergic symptoms such as itching, urticaria and allergic rhinitis. These medicines relieve histamine-mediated symptoms but do not stop mast-cell degranulation, do not remove an allergen, and do not replace intramuscular adrenaline in anaphylaxis. H2 blockers are a different class, used mainly to reduce gastric acid—not routine allergy medicine. Good prescribing means matching receptor blockade to the diagnosis while preventing sedation, antimuscarinic toxicity, interactions and unsafe self-medication.
Do not miss anaphylaxis
Airway swelling, wheeze/stridor, collapse, persistent hypotension or rapidly progressive multisystem allergic symptoms require immediate emergency assessment and intramuscular adrenaline according to protocol. H1 antihistamines treat itch/hives but act too slowly and do not reverse life-threatening airway obstruction or shock. Never delay adrenaline for an antihistamine.
Lesson map
Synthesis, storage, release and receptor actions.
First versus second generation, individual medicines and clinical selection.
Acid suppression, individual agents and their distinctive risks.
Rhinitis, urticaria, motion sickness, itch, nausea and emergency allergy.
Sedation, anticholinergic effects, interactions, children, pregnancy and overdose.
Cases, exam traps and OSCE counselling.
1. Histamine: where it comes from and why it matters
Histamine is an endogenous amine formed from the amino acid histidine by histidine decarboxylase. It is stored preformed in granules, particularly in tissue mast cells (skin, airway and gastrointestinal tract) and circulating basophils. It is also a neurotransmitter in the CNS and has roles in gastric enterochromaffin-like/parietal-cell signalling.
| How histamine is released | Examples | Clinical implication |
|---|---|---|
| IgE-mediated immediate hypersensitivity | Allergen cross-links IgE bound to mast-cell/basophil Fcε receptors. | Classic urticaria, allergic rhinitis, allergic conjunctivitis and anaphylaxis; histamine is only one of several mediators. |
| Non-IgE mast-cell activation | Some drugs, physical stimuli, infections and other direct triggers. | Do not label every histamine-mediated reaction as a true IgE allergy without clinical assessment. |
| Cell injury/immune inflammation | Tissue inflammation and mast-cell activation in skin/airway/gut. | H1 drugs are useful when histamine drives symptoms; they are often insufficient for complex inflammatory disease. |
The immediate “triple response” of histamine
- Redness: arteriolar vasodilation.
- Flare: axon-reflex-mediated surrounding vasodilation.
- Wheal: increased post-capillary venular permeability causes oedema. H1 antihistamines suppress this wheal-and-flare response, which is a useful pharmacological demonstration but not the entire allergic cascade.
2. Histamine receptors: the map that prevents confusion
| Receptor | Important location / signalling | Major effects of histamine | Clinical drug relevance |
|---|---|---|---|
| H1 | Endothelium, smooth muscle, sensory nerves, heart and CNS; predominantly Gq. | Itch, sensory-nerve stimulation; bronchial/gut smooth-muscle contraction; vasodilation via NO; increased vascular permeability; wakefulness/vestibular signalling. | H1 antihistamines for urticaria, rhinitis, itch, allergy symptoms; selected older drugs for motion sickness/nausea/short-term sedation. |
| H2 | Gastric parietal cells, heart, vascular smooth muscle; Gs. | Increases gastric acid secretion; contributes to cardiac stimulation and vasodilation. | H2 receptor antagonists reduce acid secretion in selected dyspepsia/ulcer/GERD-related indications. They are not a substitute for H1 treatment of allergy. |
| H3 | Predominantly presynaptic CNS receptor; Gi. | Autoreceptor/heteroreceptor that reduces release of histamine and other neurotransmitters; influences arousal. | Not a routine bedside anti-allergy target. Specialist H3-directed therapy exists in limited indications in some settings. |
| H4 | Immune cells including eosinophils, mast cells, dendritic cells and T cells. | Immune-cell chemotaxis and inflammatory signalling. | Research target; no routine standard H4 antagonist for everyday allergic prescribing. |
3. How H1 antihistamines work—and what they cannot do
Most H1 antihistamines are better described as inverse agonists: they stabilise the inactive receptor state and reduce constitutive H1 activity, while also competitively opposing histamine. They are most effective before or early in histamine-driven symptoms. They do not neutralise histamine already released, block leukotrienes or prostaglandins, prevent mast-cell degranulation, or cure the underlying sensitisation.
Why an antihistamine cannot be the sole treatment for anaphylaxis
Anaphylaxis is not “just histamine.” It involves airway oedema, bronchospasm, vasodilation, capillary leak and shock from multiple mediators. Adrenaline provides rapid α- and β-adrenergic support; an H1 antihistamine may relieve persistent skin symptoms later but cannot restore perfusion or reliably relieve severe bronchospasm/laryngeal oedema.
4. H1 antihistamines: first generation versus second generation
| Feature | First generation (“sedating”) | Second generation (“less sedating”) |
|---|---|---|
| CNS penetration | Cross blood–brain barrier readily; central H1 blockade. | Lower CNS penetration because of polarity/P-glycoprotein transport; sedation is lower, not impossible. |
| Receptor selectivity | Often non-selective: antimuscarinic, α-blocking and sometimes serotonergic actions. | More peripheral H1 selectivity with fewer off-target actions. |
| Duration | Often shorter, commonly several daily doses; exceptions exist. | Usually longer acting—often once daily—supporting adherence. |
| Adverse-effect pattern | Drowsiness, impaired reaction time, confusion/delirium in older people, dry mouth, blurred vision, constipation and urinary retention. | Headache, dry mouth/fatigue or occasional drowsiness; much less antimuscarinic burden. Cetirizine/levocetirizine can still sedate some patients. |
| Best role | Selected motion sickness, short-term nausea/vertigo, selected itch or short-term night use when sedation is deliberately acceptable. | Preferred routine choice for allergic rhinitis and chronic urticaria because daytime function is preserved better. |
First-generation H1 groups and examples from the supplied lecture
Diphenhydramine, dimenhydrinate. Prominent sedation and antimuscarinic effect; useful in selected motion-sickness/nausea settings, but unsafe before driving.
Chlorphenamine (chlorpheniramine), pheniramine. Often less sedating than some older agents but still impair alertness and have antimuscarinic effects.
Hydroxyzine, cyclizine. Hydroxyzine is sedating and its metabolite includes cetirizine; cyclizine is used for nausea/vertigo in appropriate settings.
Promethazine. Marked sedation and antimuscarinic action; used selectively for allergy/nausea, with major caution in children and respiratory/CNS depression.
Cyproheptadine. H1 blockade plus antiserotonergic/antimuscarinic actions; specialist/selected uses, not a routine first-choice non-sedating allergy medicine.
Cinnarizine is used in some settings for vertigo/motion sickness; it is sedating and has additional pharmacology.
Second-generation H1 drugs
| Drug | High-yield pharmacology and use | Key safety/selection point |
|---|---|---|
| Cetirizine | Active carboxylated metabolite of hydroxyzine; rapid peripheral H1 effect and common once-daily use for allergic rhinitis/urticaria. | Classed less sedating, but sleepiness is common enough to matter. Assess driving/work-at-height response individually; adjust/avoid as appropriate in renal impairment. |
| Levocetirizine | Active enantiomer of cetirizine; used for rhinitis/urticaria. | Still may cause somnolence; do not assume “newer” means risk-free. |
| Loratadine | Long-acting, minimally sedating piperidine; metabolised to active desloratadine. | Review hepatic function and interaction risk; appropriate for many daytime allergy presentations. |
| Desloratadine | Active metabolite of loratadine; peripheral H1 blocker. | Long acting and usually low sedation; check product-specific age/renal/hepatic advice. |
| Fexofenadine | Active metabolite related to terfenadine; very low brain penetration and generally very low sedation. | Useful when driving alertness is critical, but still warn about individual impairment. Fruit juices and some antacids can reduce absorption—follow product advice. |
| Terfenadine / astemizole | Historically important second-generation agents. | Teaching point, not routine prescribing: cardiac QT-prolongation/torsades risk with interactions led to restriction/withdrawal in many markets. Prefer current locally available alternatives. |
| Acrivastine / bilastine (availability varies) | Newer/less sedating options in some formularies. | Choose based on local availability, age, renal/hepatic status and interaction profile—not advertising claims. |
5. Individual H1 medicines: clinical pearls
- Hydroxyzine: orally or parenterally administered in some settings; sedating and anticholinergic. Its hepatic metabolite includes cetirizine. It may be useful when itch/anxiety/sedation is relevant, but avoid casually combining it with other sedatives and be alert to cardiac-risk warnings in local product information.
- Pheniramine/chlorphenamine: useful older agents for short-term allergic symptoms; can cause drowsiness, dry mouth, blurred vision, constipation and urinary hesitation. They are poor choices for patients needing unimpaired alertness.
- Diphenhydramine: strongly sedating; used for allergy symptoms and in some antiemetic/motion-sickness/sleep preparations. Do not combine with alcohol, opioids, benzodiazepines or another sedating antihistamine unless specifically directed.
- Promethazine: very sedating and antimuscarinic. It can cause profound CNS/respiratory depression in vulnerable patients and has important paediatric restrictions—always use age-specific local guidance.
- Dimenhydrinate/cyclizine: selected antiemetic/vestibular applications reflect central H1/antimuscarinic effects. They do not treat the cause of recurrent vomiting or vertigo.
- Cyproheptadine: has H1 and serotonin-antagonist properties; can stimulate appetite but should not be used routinely as an appetite drug without diagnosing the cause of poor growth/weight loss.
- Doxepin: a tricyclic antidepressant with potent H1/H2 activity. Systemic use may be considered for difficult pruritus/urticaria under supervision; topical doxepin can cause drowsiness through absorption and contact dermatitis—do not treat it as harmless cream.
6. Pharmacokinetics and drug interactions
Most classical H1 antihistamines are absorbed orally; some have parenteral/topical preparations. Many are hepatically metabolised and renally excreted as metabolites. Older agents often have action lasting several hours; many modern agents have 12–24-hour action. Fexofenadine differs in having limited metabolism and substantial faecal excretion. Individual product information—not a generic class rule—must guide dose adjustment.
| Interaction / factor | Why it matters | Safe response |
|---|---|---|
| Alcohol, opioids, benzodiazepines, sedative hypnotics, antipsychotics and other CNS depressants | Additive sedation, impaired coordination/judgement and possibly respiratory depression in vulnerable patients. | Avoid or use only on explicit prescriber/pharmacist advice; warn not to drive or operate machinery until effect is known. |
| Other antimuscarinic drugs (e.g. some antidepressants, antipsychotics, antispasmodics) | Increased dry mouth, constipation, blurred vision, delirium and urinary retention. | Especially avoid unnecessary first-generation burden in older people, glaucoma, prostatic enlargement/retention and bowel obstruction risk. |
| Enzyme inhibitors (some macrolides, azole antifungals, cimetidine, HIV-related medicines) | May increase concentrations of particular antihistamines; historical QT-risk drugs illustrate why this matters. | Check agent-specific interaction source; avoid obsolete QT-risk combinations. |
| Enzyme inducers (rifampicin/rifabutin, carbamazepine, phenytoin and others) | Can reduce concentrations/effect of certain antihistamines. | Review clinical response and seek medicine-specific advice rather than escalating blindly. |
| Beta-blockers | Some older antihistamines may alter beta-blocker metabolism; beta-blockade can also complicate treatment of anaphylaxis. | Medication reconciliation is essential; emergency anaphylaxis care remains protocolled. |
| Duplicate OTC cold/flu/night-time products | Common hidden source of multiple sedating antihistamines, paracetamol or decongestants. | Ask exactly what the patient bought; never advise two oral antihistamines together unless a clinician has explicitly planned it. |
7. Therapeutic uses: choose the symptom pattern and the drug target
| Condition | Role of antihistamine | Practical choice/caution |
|---|---|---|
| Allergic rhinitis / hay fever | Relieves sneezing, itch, rhinorrhoea and eye symptoms; less effective for marked nasal blockage. | Non-sedating oral or intranasal H1 agent is often suitable. Persistent/moderate-severe disease often needs intranasal corticosteroid and allergen avoidance; do not keep escalating sedating tablets for obstruction. |
| Acute and chronic urticaria | Second-generation H1 antihistamine is core symptomatic therapy. | Look for angioedema/anaphylaxis, drug triggers, infection and chronic disease. Dosing escalation or add-on treatment should follow a guideline/specialist plan, not unsupervised stacking of sedating products. |
| Allergic conjunctivitis | Oral or topical H1 therapy can reduce itch/watering. | Pain, photophobia, reduced vision or unilateral marked redness needs eye assessment—not repeated self-treatment. |
| Atopic dermatitis / generalised itch | May reduce sleep-disrupting itch in selected patients. | Does not replace emollients, trigger control, topical anti-inflammatory therapy or diagnosis of scabies/fungal/systemic causes of itch. |
| Motion sickness/vertigo-associated nausea | Some first-generation centrally acting agents prevent/treat symptoms. | Use short term and counsel about drowsiness/antimuscarinic effects. Exclude neurological or ear emergencies when indicated. |
| Short-term insomnia | Some older agents sedate. | Not preferred chronic insomnia management; tolerance, next-day impairment, falls and anticholinergic burden are important. |
| Drug/allergic reaction adjunct | May relieve itching/hives after emergency assessment. | Never use as sole therapy for anaphylaxis; identify/record true culprit where appropriate. |
8. H2-receptor antagonists: include them, but keep their role separate
H2 antagonists reduce gastric acid secretion by blocking parietal-cell H2 receptors. The supplied lecture lists cimetidine, ranitidine and famotidine. Their common teaching indications include acid-related dyspepsia, peptic ulcer disease, reflux-related symptoms and hypersecretory states such as Zollinger–Ellison syndrome. Current acid-suppression practice is condition- and formulary-specific; proton-pump inhibitors are often preferred for many indications. H2 blockade is not a replacement for H1 blockade in ordinary allergy care.
| H2 agent | Distinctive point | Safety / practice note |
|---|---|---|
| Cimetidine | Oldest widely taught H2 blocker; inhibits several CYP enzymes and has antiandrogenic effects. | More interaction risk; possible confusion/delirium in older people, gynaecomastia/sexual dysfunction with exposure, and rare blood dyscrasia. Prefer an alternative when appropriate. |
| Famotidine | Potent H2 antagonist with fewer CYP interactions than cimetidine. | Renal-dose considerations; review current local formulary and indication. |
| Ranitidine | Historically used widely. | Do not reproduce old prescribing blindly: it was withdrawn/suspended in many countries because of NDMA impurity concerns. Use current Ugandan/local regulatory and formulary status. |
9. Adverse effects, contraindications and overdose
| Problem | Most associated drugs / mechanism | Prevention and response |
|---|---|---|
| Sedation and impaired performance | First-generation CNS H1 blockade; possible even with “non-drowsy” products. | No driving, machinery, climbing or alcohol until individual response is known. Prefer second generation for routine daytime allergy. |
| Antimuscarinic syndrome | Older H1 drugs: dry mouth, blurred vision, constipation, urinary retention, tachycardia, confusion. | Use great caution/avoid in older adults, narrow-angle glaucoma, prostatic obstruction/retention, severe constipation/ileus and cognitive vulnerability. |
| Paradoxical CNS excitation | Especially children or overdose of sedating agents. | Irritability, agitation, tremor, insomnia or seizures may occur; do not respond by giving more medicine. |
| Falls/delirium | Sedation + anticholinergic burden, especially in frail older adults. | Medication review; avoid routine first-generation agents when a less sedating alternative works. |
| QT prolongation/arrhythmia | Specific agents/interactions—historically terfenadine and astemizole; some medicines require caution. | Do not use withdrawn/obsolete agents; check individual product warnings and interacting CYP inhibitors. |
| Local/contact reactions | Topical agents such as doxepin or other preparations. | Stop if dermatitis worsens; reassess diagnosis and vehicle/allergy. |
| Acute overdose | Usually first-generation agents. | May cause agitation, hallucinations, seizures, coma, arrhythmia, hyperthermia and respiratory/cardiovascular failure. Urgent poison/emergency assessment—supportive management is protocolled. |
10. Pregnancy, lactation, children and older people
Do not rely on old FDA letter categories in lecture slides. Non-drug measures and local therapy may be useful; choose medicine only after checking current obstetric/formulary guidance. Do not assume every “newer” drug is better documented.
Some antihistamines enter milk. Sedating first-generation drugs may cause infant drowsiness, irritability or poor feeding; select agent/timing using current lactation guidance.
Use age- and weight-specific formulations/doses only. Avoid using a sedating antihistamine as a routine sleep medicine; combination cough/cold products create overdose risk.
Highest burden from sedation, falls, delirium, constipation and urinary retention. A second-generation agent is usually a safer routine choice where clinically suitable.
Drug-specific clearance differs. Check current dose guidance, especially for cetirizine/levocetirizine and H2 antagonists.
“Non-drowsy” is not a guarantee. Ask about sleepiness and do not recommend a first-generation product immediately before driving or work at height.
11. Counselling checklist, cases and OSCE answers
Case 1: allergic rhinitis in a boda-boda rider
Choose a low-sedating second-generation H1 option rather than diphenhydramine/promethazine. Ask about predominant congestion (may need intranasal corticosteroid), asthma symptoms, other sedatives/alcohol, and driving impairment. Explain that a “non-drowsy” tablet can still make some people sleepy.
Case 2: hives with lip swelling and wheeze
This is not a “give chlorphenamine and wait” scenario. Assess ABCs and treat suspected anaphylaxis with intramuscular adrenaline/emergency protocol. Antihistamine is an adjunct for skin symptoms after life-saving treatment.
Case 3: older man with BPH and glaucoma requests a night-time cold product
Screen for a sedating/antimuscarinic antihistamine. It can precipitate urinary retention, blurred vision, constipation, confusion and falls. Offer diagnosis-specific safer advice instead of an automatic OTC recommendation.
Case 4: chronic urticaria not controlled by one tablet
Confirm diagnosis and red flags, adherence and triggers. Do not tell the patient to mix several OTC antihistamines. Guideline-directed optimisation/referral is safer than unplanned duplication.
- OSCE—mechanism: H1 antihistamines are inverse agonists/competitive antagonists at H1 receptors; they reduce histamine-mediated itch, vasodilation and permeability but do not stop degranulation.
- OSCE—first versus second generation: first-generation drugs cross the BBB and have sedating/antimuscarinic effects; second-generation agents are more peripheral and longer acting, so are preferred for routine allergy.
- OSCE—core safety counselling: check duplicates in cold/flu products, avoid alcohol/CNS depressants, do not drive if sleepy, avoid unplanned combination of antihistamines, and seek urgent help for anaphylaxis signs.
- Exam trap: H2 blockers reduce gastric acid. They are not the main drugs for allergic rhinitis or anaphylaxis.
- Exam trap: antihistamine may reduce hives but does not replace intramuscular adrenaline in anaphylaxis.
Further study and source trail
Supplied course source: Antihistaminics—SlideShare. Clinical expansion: NHS antihistamine safety information, NICE allergic-rhinitis management, and MedlinePlus allergy-medicine guidance. Use current local formulary/protocol for doses, paediatrics, pregnancy/lactation, emergency allergy, renal/hepatic adjustment and regulatory availability.
